| Literature DB >> 28859083 |
Nerissa Nance1, Prosper Pendo2, Joseph Masanja3, David Paul Ngilangwa3, Karen Webb4, Rita Noronha5, Sandra I McCoy1.
Abstract
INTRODUCTION: Community health workers (CHWs) are lay workers who have the potential to enhance services to prevent mother-to-child HIV transmission (PMTCT) and improve the health of women living with HIV infection. We conducted a cluster-randomized trial of an intervention to integrate CHWs with 'Option B+' PMTCT services in Shinyanga Region, Tanzania.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28859083 PMCID: PMC5578486 DOI: 10.1371/journal.pone.0181919
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Trial profile.
Fig 2Baseline and endline cohort timeline and data collection periods for the impact evaluation of a CHW-based intervention for PMTCT in Tanzania, 2014–2015.
Baseline site-level characteristics, by study arm, Tanzania, 2014,.
| Treatment sites | Control Sites | p-value | |
|---|---|---|---|
| Total number of sites | 15 | 17 | — |
| — | |||
| Type of facility (%) | 0.27 | ||
| Government health center | 53.2 | 76.2 | |
| Government dispensary | 25.8 | 23.8 | — |
| Religious/voluntary hospital | 6.4 | 0 | — |
| Religious/voluntary health center | 14.6 | 0 | — |
| Estimated population in catchment area | 16321(1895) | 17015 (2896) | 0.84 |
| Number of staff | 16.0 (1.7) | 18.8 (3.4) | 0.50 |
| Average number of CHWs per site mean (SE) | 15.2 (2.6) | 9.2 (1.0) | 0.03 |
| Average number of CHWs per capita | 0.07 | 0.13 | 0.06 |
| Frequency of CHW meetings (%) | 0.60 | ||
| 1–2 times/month | 0 | 6.4 | — |
| 3–4 times/month | 34.5 | 35.6 | — |
| >4 times/month | 65.6 | 58.0 | — |
| — | |||
| Number of days per week ANC services are available (mean (SE)) | 4.2 (0.4) | 4.9 (0.3) | 0.14 |
| Provision of ART services, including Option B+ services (%) | 100 | 100 | — |
| Provision of postnatal services (%) | 0.35 | ||
| At facility | 100.0 | 94.4 | — |
| Referral to another facility | 0 | 5.6 | — |
| Provision of labor and delivery services (%) | 0.25 | ||
| At facility | 83.3 | 100.0 | — |
| Referral to another facility | 11.3 | 0 | — |
| Both | 5.6 | 0 | — |
| Adherence counseling provided (%) | 38.7 | 33.7 | 0.95 |
| Every CTC visit | 54.9 | 60.6 | — |
| Treatment initiation only | 6.4 | 5.6 | — |
| — | |||
| Mean number of missing women from baseline sample | 4.7 (1.5) | 2.7 (0.62) | 0.12 |
| Early infant HIV diagnosis by 6–18 months postpartum (% among HIV-exposed infants) | 37.6 (3.4) | (1.9) | 0.03** |
** Significant at the α = 0.05 level
* Significant at the α = 0.10 level
a) Estimates are weighted by site size (large vs. small)
b) Statistical significance of differences between control and treatment groups determined using chi-square tests for categorical variables and t-tests for continuous variables
c) SE = standard error
d) To calculate average number of CHWs per capita, the number of CHWs at the site was divided by the estimated population in the catchment area
e) Women were excluded from the sample if they did not have necessary identifying information to link them across records (n = 123)
Baseline and endline outcomes among HIV-positive pregnant and postpartum women in Tanzania, stratified by treatment group, 2014–2015.
| Control Group | Treatment Group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Baseline | Endline | Difference | Baseline | Endline | Unadjusted DiD | Adjusted DiD | |||
| 1830 | 590 | 374 | — | 562 | 304 | — | — | |||
| 1830 | 34.6 (2.6) | 47.3 (5.6) | 12.7 (0.6, 24.7) | 35.3 (1.9) | 45.3 (4.6) | -2.7 (-16.3, 10.9) | -4.5 (-17.5, 8.6) | |||
| Full Sample | ||||||||||
| 1348 | 46.4 (2.6) | 59.0 (4.4) | 12.6 (4.5, 20.8) | 47.9 (3.0) | 65.6 (3.4) | 5.0 (-5.9, 15.9) | 0.9 (-11.8, 13.7) | |||
| Women with evidence of care | ||||||||||
| 1544 | 55.1 (4.8) | 46.0 (3.5) | -9.1 (-16.9, -1.3) | 46.1 (3.3) | 45.1 (3.6) | 8.0 (-2.3, 18.4) | 5.9 (-2.4, 14.2) | |||
| 787 | 27.3 (0.6) | 24.3 (1.1) | -3.0 (-5.2, -0.8) | 27.2 (0.8) | 26.7 (1.3) | 2.5 (-1.6, 6.5) | 2.0 (-2.0, 6.0) | |||
| 820 | 21.2 (3.1) | 22.8 (3.1) | 1.6 (-2.9, 6.1) | 16.2 (3.8) | 29.1 (4.8) | 11.3 (-0.7, 23.3) | 9.5 (-2.9, 22.0) | |||
| 820 | 34.9 (4.4) | 41.6 (4.2) | 6.7 (1.5, 11.9) | 27.8 (4.1) | 46.7 (5.9) | 12.2 (-0.7, 25.1) | 8.9 (-3.2, 21.1) | |||
* significant at the α = 0.10 level
** significant at the α = 0.10 level
a) Estimates were weighted for selection, site size and, at baseline, missing women
b) Women retained 0–90 days postpartum, calculated for n = 1830 all women in the sample, and n = 1348 women with evidence of HIV care
c) Observed intraclass correlation coefficient (ICC) for primary outcome of retention in care = 0.04
d) Number of women initiating ART calculated for the n = 1544 women who did not have evidence of beginning ART prior to pregnancy; women were considered to have initiated ART if they had any evidence of ART use between pregnancy and 90 days postpartum
e) ART initiation timing calculated for n = 787 women who had an ARV start date on record, and who began ART after pregnancy; women were considered to have initiated ART if they had any evidence of ART use between pregnancy and 90 days postpartum
f) MPR ≥95 (and MPR≥80) are the women that have 95% adherence (or 80% adherence) or greater according to the medicine possession ratio (MPR) calculation, defined as the number of pill days dispensed over the number of days elapsed from the infant’s birth to 90 days postpartum
g) MPR calculated for n = 820 women who had complete ARV dispensing information
h) DiD = difference-in-differences estimate, generated through the linear regression of the outcome with an interaction variable for time and treatment status (see methods); adjusted model additionally adjusted for factors imbalanced at baseline (HEID testing and number of CHWs at the facility)
i) SE = standard error; CI = confidence interval
j) Difference between measurements at baseline and endline in control group
Effect of the intervention on PMTCT indicators, stratified by treatment intensity, Tanzania, 2014–2015.
| Outcome | Baseline (births in 2014) | Endline (births in 2015) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Tx | Control | Tx intensity | Control | DiD | DiD Adjusted | ||||||
| High | Low | High | Low | High | Low | High | Low | |||||
| (95% CI | (95% CI) | (95% CI) | (95% CI) | |||||||||
| 1830 | 171 | 391 | 590 | 94 | 210 | 374 | _ | _ | _ | _ | ||
| 1830 | 35.0% | 35.6% | 34.6% | 48.6% | 42.6% | 47.3% | 0.9 (-15.5, 17.3) | -5.6 (-19.1, 7.8) | -6.8 (-19.9, 6.3) | -2.0 (-16.0, 11.9) | ||
| Full Sample | ||||||||||||
| 1348 | 51.5% | 45.3% | 46.4% | 70.2% | 61.9% | 59.0% | 6.1 (-9.1, 21.3) | 4.0 (-7.5, 15.5) | -3.6 (-16.4, 9.1) | 4.8 (-8.9, 18.4) | ||
| Women with evidence of care | ||||||||||||
| 1544 | 40.6% | 50.9% | 55.1% | 45.9% | 44.5% | 46.0% | 14.4 (4.9, 23.8) | 2.7 (-10.0, 15.3) | 8.1 (-2.6, 18.8) | 3.8 (-6.1, 13.6) | ||
| 787 | 27.9 | 26.7 | 27.3 | 23.3 | 29.3 | 24.3 | -1.6 (-6.5, 3.2) | 5.6 (2.8, 8.5) | -1.5 (-6.1, 3.0) | 5.3 (2.4, 8.2) | ||
| 820 | 18.8% | 14.3% | 21.2% | 34.8% | 24.1% | 22.8% | 14.3 (2.0, 26.6) | 8.2 (-9.2, 25.5) | 13.6 (2.5, 24.6) | 4.8 (-14.9, 24.4) | ||
| 820 | 33.2% | 24.1% | 34.9% | 52.5% | 41.8% | 41.6% | 12.6 (-2.4, 27.5) | 11.0 (-6.8, 28.7) | 11.6 (-1.6, 24.9) | 5.0 (-11.5, 21.4) | ||
* significant at the α = 0.10 level
**significant at the α = 0.05 level
***significant at the α = 0.01 level
a) estimates were weighted for selection, site size and, at baseline, missing women (see methods)
b) Tx = treatment, grouped into a “high” category, scores above the median, or a “low” category, at or below the median (see methods)
c) Women retained in care calculated for n = 1830 all women in the sample, and n = 1348 women with evidence of HIV care
d) Number of women initiating ART calculated for the n = 1544 women who did not have evidence of beginning ART prior to pregnancy; women were considered to have initiated ART if they had any evidence of ART use between pregnancy and 90 days postpartum
e) Timing of ART initiation calculated for n = 787 women who had an ARV start date on record, and who began ART after pregnancy
f) MPR ≥95 (and MPR≥80) are the women that have 95% adherence (or 80% adherence) or greater according to the MPR calculation, defined as the number of pill days dispensed over the number of days elapsed from the infant’s birth to 90 days postpartum
g) MPR calculated for n = 820 women who had complete ARV dispensing information
h) DiD = difference-in-differences estimate, generated through the linear regression of the outcome with an interaction variable for time and treatment status (see methods)
i) CI = confidence interval
j) Unadjusted for baseline imbalance
k) Adjusted for average number of CHWs per site and percent of HEID testing